Prognostic factors in stage I carcinoma of the cervix

Boyce, John; Fruchter, Rachel G.; Nicastri, Anthony D.; Ambiavagar, Poh-Choon; Reinis, Maria Skerlavay; Nelson, James H.

doi:10.1016/0090-8258(81)90145-1

Cited by 124 publications

(41 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parametriyal invazyon tümör gradı, derin stromal invazyon ve LVSI varlığı ile iliş-kilidir (24). İnvazyonun derinliğinin artması anlamlı olarak nodal yayılım, rekürrens ve sağkalımda azalma ile ilişkilidir (25). LVSI ile birlikte invazyon derinliği orta risk faktörleri olarak düşünülmektedir ve lokal rekürrensleri azaltmak için postoperatif adjuvan radyoterapi gereksinimi doğurmakta-dır (26).…”

Section: İzlemunclassified

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Yavaş¹,

Doğan²,

Yavaş³

et al. 2015

Akd Med J

View full text Add to dashboard Cite

ÖZAmaç: Radyoterapi tedavisi alan jinekolojik tümörlü hastaların değerlendirilmesi. Gereç ve Yöntemler:Haziran 2010-Ocak 2013 tarihleri arasında küratif radyoterapi (RT) uygulanan 78 jinekolojik tümörlü hasta retrospektif olarak değerlendirildi. Bulgular:Olguların 33'ü serviks kanseri, 44'ü endometriyum kanseri ve 1'i endoservikal kanal tü-mörü nedeni ile tedavi edildi. Medyan yaşı 56 idi (aralık: 34-83 ). Ortalama izlem süresi 23,9±1,4 ay idi. Tanı anında 18 hasta (%23,1) premenopozal, 60 hasta (%74,9) postmenopozaldi. Endometriyum kanseri nedeni ile opere edilen olguların 31'i adjuvan RT alırken; 9 olgu postoperatif KT ve RT aldı. Endometriyum kanseri tanısı olan 5 hasta nüks nedeni ile kurtarma cerrahisi ardından RT aldı. Serviks kanseri nedeni ile RT uygulanan hastaların 16'sına lokal ileri evre serviks kanseri nedeni ile defi nitif kemoradyoterapi uygulandı. On (%30,3) serviks kanseri tanılı olgu ise adjuvan RT; 6 hasta (%18,2) adjuvan kemoradyoterapi (KRT), 1 olgu ise (%3) kurtarma amaçlı RT aldı. Endoservikal kanal tümörü tanısı olan hastaya adjuvan KRT uygulandı. Endometriyum kanseri nedeni ile RT uygulanan hastalarda medyan sağkalım 26,3 ay, serviks kanseri nedeni ile RT uygulanan hastalarda ise 21,1 ay olarak bulundu. Endometriyum kanseri tanısı ile tedavi edilen hastalarda cox-regresyon analizinde lokal nüks (p=0,046) , tümör çapı (p= 0,030) ve evrenin (p= 0,036) sağkalım ile ilişkisi gös-terilirken; lenfovasküler alan invazyonu (p=0,711), myometriyal invazyonun (p=0,684) sağkalım ile ilişkisi gösterilememiştir. Serviks kanseri nedeni ile tedavi edilen hastalarda ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki gösterilmiştir (p=0,043).Sonuç: Endometriyum kanserinde lokal nüks , tümör çapı ve evre sağkalım ile ilişkilidir. Serviks kanserinde ise lenf nodu pozitifl iği ile progresyonsuz hastalık arasında ilişki mevcuttur. Results:We treated 33, 44 and 1 patient for cervical cancer, endometrial cancer and endocervical canal tumor respectively. The median age was 56 years (34-83). The mean follow-up period was 23.9±1.4 months. At the time of diagnosis, 18 (23.1%) patients were premenopausal whereas 60 (74.9%) patients were postmenopausal. Thirty-one endometrial cancer patients received adjuvant RT while 9 received adjuvant chemotherapy and RT. Five of the patients with a diagnosis of recurrent endometrial cancer received RT after salvage surgery. Sixteen patients with locally advanced cervical cancer were treated with defi nitive chemoradiotherapy. Ten patients (30.3%) who were operated on for cervical cancer were administered adjuvant RT whereas 6 patients (18.2%) received adjuvant chemoradiotherapy. The patient with endocervical canal tumor received adjuvant chemoradiotherapy. The median overall survivals were 26.3 and 21.1 months for patients with endometrial and cervical cancer respectively. Cox-regression analyses revealed that there was a relationship between the overall

show abstract

Section: İzlemunclassified

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Yavaş¹,

Doğan²,

Yavaş³

et al. 2015

Akd Med J

View full text Add to dashboard Cite

show abstract

“…Именно тогда и возникло предположение о губительном воздействии на опухоль каких-то факторов, появляющихся в ответ на введение бактериальных вытяжек [3,6,7,8]. В 1962 году O`Malley с соавторами в опытах на мышах доказали, что геморрагические некрозы в опухолях после введения бактериального липополисахарида (ЛПС) обусловлены действием не самого ЛПС, а какого-то промежуточного фактора, который появляется в сыворотке крови в ответ на инъекцию ЛПС [1,3,4,6]. Эта сыворотка обладала способностью убивать опухолевые клетки при введении другим мышам, которые не получали инъекций ЛПС.…”

unclassified

“…Так, возникла новая область онкологии -онкоиммунология, формирование которой началось с открытия онкогенов и разработки методов формирования специфического иммунного ответа против них [5,7]. Остаются, однако, по-прежнему нерешенными фундаментальные вопросы, касающиеся экспрессии специфических антигенов опухолями человека, иммунного ответа на этот антиген и возможности влиять на этот ответ с целью борьбы с опухолью [2,4].…”

unclassified

Modern Immunopharmacotherapy in Complex Treatment of Cervical Cancer

Kamishov¹,

Scientific²

2018

JSE

View full text Add to dashboard Cite

show abstract

“…The most important and widely studied prognostic variables for cervical cancer are lymph node spread, tumor size, involvement of parametrial tissue, depth of invasion, and lymphovascular invasion. [3][4][5][6] The incidence of patients with lymph node involvement increased with parametrial extension (P < .01). The corrected 5-year survival rates were 94% for patients with stage IB disease, 95% for patients with stage IIA disease, and 78% for patients with stage IIB disease.…”

mentioning

confidence: 99%

“…The corrected 5-year survival rates were 94% for patients with stage IB disease, 95% for patients with stage IIA disease, and 78% for patients with stage IIB disease. 3 In 1 study that was conducted on 628 patients who had cervical cancer between stage IA1 and stage IIB, the investigators reported that, with parametrial extension, lymph node metastasis rates increased significantly from 12% to 32% for patients with stage IB disease (P < .005), from 9% to 70% for patients with stage IIA disease (P < .001), and from 29% to 58% for patients with stage IIB disease (P < .001). 4 Similarly, it was reported that lymph node status, parametrial invasion, lymphovascular space invasion, and a histology of pure adenocarcinoma were important histopathologic prognostic factors for patients with early-stage cervical carcinoma who underwent radical surgery.…”

mentioning

confidence: 99%

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Kumar

Dadparvar

2007

Cancer

View full text Add to dashboard Cite

Lentivirus‐derived vectors (LVs) were studied for the generation of stable recombinant Chinese hamster ovary (CHO) cell lines. Stable pools and clones expressing the enhanced green fluorescent protein (eGFP) were selected via fluorescence‐activated cell sorting (FACS). For comparison, cell pools and cell lines were also generated by transfection, using the LV transfer plasmid alone. The level and stability of eGFP expression was greater in LV‐transduced cell lines and pools than in those established by transfection. CHO cells were also infected at two different multiplicities of infection with an LV co‐expressing eGFP and a tumor necrosis factor receptor:Fc fusion protein (TNFR:Fc). At 2‐day post‐infection, clonal cell lines with high eGFP‐specific fluorescence were recovered by FACS. These clones co‐expressed TNFR:Fc with yields of 50–250 mg/L in 4‐day cultures. The recovered cell lines maintained stable expression over 3 months in serum‐free suspension culture without selection. In conclusion, LV‐mediated gene transfer provided an efficient alternative to plasmid transfection for the generation of stable and high‐producing recombinant cell lines. Biotechnol. Bioeng. 2011; 108:600–610. © 2010 Wiley Periodicals, Inc.

show abstract

Prognostic factors in stage I carcinoma of the cervix

Cited by 124 publications

References 9 publications

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Modern Immunopharmacotherapy in Complex Treatment of Cervical Cancer

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Contact Info

Product

Resources

About

Prognostic factors in stage I carcinoma of the cervix

Cited by 124 publications

References 9 publications

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Radiotherapy in Gynecological Cancers: Analysis of Treatment Results and Prognostic Factors

Modern Immunopharmacotherapy in Complex Treatment of Cervical Cancer

18F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Contact Info

Product

Resources

About

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix